Early remote ischaemic preconditioning leads to sustained improvement in allograft function after live donor kidney transplantation: long-term outcomes in the REnal Protection Against Ischaemia-Reperfusion in transplantation (REPAIR) randomised trial.


Journal

British journal of anaesthesia
ISSN: 1471-6771
Titre abrégé: Br J Anaesth
Pays: England
ID NLM: 0372541

Informations de publication

Date de publication:
11 2019
Historique:
received: 26 04 2019
revised: 08 07 2019
accepted: 08 07 2019
pubmed: 16 9 2019
medline: 29 10 2019
entrez: 16 9 2019
Statut: ppublish

Résumé

The REnal Protection Against Ischaemia-Reperfusion in transplantation (REPAIR) RCT examined whether remote ischaemic preconditioning (RIPC) improved renal function after living-donor kidney transplantation. The primary endpoint, glomerular filtration rate (GFR), quantified by iohexol at 12 months, suggested that RIPC may confer longer-term benefit. Here, we present yearly follow-up data of estimated GFR for up to 5 yr after transplantation. In this double-blind, factorial RCT, we enrolled 406 adult live donor kidney transplant donor-recipient pairs in 15 European transplant centres. RIPC was performed before induction of anaesthesia. RIPC consisted of four 5 min inflations of a BP cuff on the upper arm to 40 mm Hg above systolic BP separated by 5 min periods of cuff deflation. For sham RIPC, cuff inflation to 40 mm Hg was undertaken. Pairs were randomised to sham RIPC, early RIPC only (immediately pre-surgery), late RIPC only (24 h pre-surgery), or dual RIPC (early and late RIPC). The pre-specified secondary outcome of estimated GFR (eGFR) was calculated from serum creatinine measurements, using the Chronic Kidney Disease Epidemiology Collaboration equation. Predefined safety outcomes were mortality and graft loss. There was a sustained improvement in eGFR after early RIPC, compared with control from 3 months to 5 yr (adjusted mean difference: 4.71 ml min RIPC safely improves long-term kidney function after living-donor renal transplantation when administered before induction of anaesthesia. ISRCTN30083294.

Sections du résumé

BACKGROUND
The REnal Protection Against Ischaemia-Reperfusion in transplantation (REPAIR) RCT examined whether remote ischaemic preconditioning (RIPC) improved renal function after living-donor kidney transplantation. The primary endpoint, glomerular filtration rate (GFR), quantified by iohexol at 12 months, suggested that RIPC may confer longer-term benefit. Here, we present yearly follow-up data of estimated GFR for up to 5 yr after transplantation.
METHODS
In this double-blind, factorial RCT, we enrolled 406 adult live donor kidney transplant donor-recipient pairs in 15 European transplant centres. RIPC was performed before induction of anaesthesia. RIPC consisted of four 5 min inflations of a BP cuff on the upper arm to 40 mm Hg above systolic BP separated by 5 min periods of cuff deflation. For sham RIPC, cuff inflation to 40 mm Hg was undertaken. Pairs were randomised to sham RIPC, early RIPC only (immediately pre-surgery), late RIPC only (24 h pre-surgery), or dual RIPC (early and late RIPC). The pre-specified secondary outcome of estimated GFR (eGFR) was calculated from serum creatinine measurements, using the Chronic Kidney Disease Epidemiology Collaboration equation. Predefined safety outcomes were mortality and graft loss.
RESULTS
There was a sustained improvement in eGFR after early RIPC, compared with control from 3 months to 5 yr (adjusted mean difference: 4.71 ml min
CONCLUSIONS
RIPC safely improves long-term kidney function after living-donor renal transplantation when administered before induction of anaesthesia.
CLINICAL TRIAL REGISTRATION
ISRCTN30083294.

Identifiants

pubmed: 31521337
pii: S0007-0912(19)30593-8
doi: 10.1016/j.bja.2019.07.019
pii:
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

584-591

Informations de copyright

Copyright © 2019 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.

Auteurs

Kristin V Veighey (KV)

Wessex Kidney Centre, Portsmouth Hospitals NHS Trust, Portsmouth, Hampshire, UK; Research and Development, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, UK. Electronic address: kristin.veighey@uhs.nhs.uk.

Jennifer M Nicholas (JM)

Clinical Trials Unit, London School of Hygiene and Tropical Medicine, London, UK.

Tim Clayton (T)

Clinical Trials Unit, London School of Hygiene and Tropical Medicine, London, UK.

Rosemary Knight (R)

Clinical Trials Unit, London School of Hygiene and Tropical Medicine, London, UK.

Steven Robertson (S)

Clinical Trials Unit, London School of Hygiene and Tropical Medicine, London, UK.

Neil Dalton (N)

Evelina London Children's Hospital, London, UK.

Mark Harber (M)

Kidney Unit, Royal Free London NHS Foundation Trust, London, UK.

Christopher J E Watson (CJE)

Department of Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Johan W De Fijter (JW)

Department of Medicine, Division of Nephrology, Leiden University Medical Centre, Leiden, The Netherlands.

Stavros Loukogeorgakis (S)

Institute of Child Health, University College London, London, UK.

Raymond MacAllister (R)

Dorset County Hospital NHS Foundation Trust, Dorset, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH